000126906 001__ 126906
000126906 005__ 20240228140853.0
000126906 0247_ $$2doi$$a10.1007/s00401-015-1405-4
000126906 0247_ $$2pmid$$apmid:25752754
000126906 0247_ $$2ISSN$$a0001-6322
000126906 0247_ $$2ISSN$$a1432-0533
000126906 0247_ $$2altmetric$$aaltmetric:3774732
000126906 037__ $$aDKFZ-2017-02934
000126906 041__ $$aeng
000126906 082__ $$a610
000126906 1001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b0$$eFirst author$$udkfz
000126906 245__ $$aIntegrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
000126906 260__ $$aBerlin$$bSpringer$$c2015
000126906 3367_ $$2DRIVER$$aarticle
000126906 3367_ $$2DataCite$$aOutput Types/Journal article
000126906 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508498578_28041
000126906 3367_ $$2BibTeX$$aARTICLE
000126906 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126906 3367_ $$00$$2EndNote$$aJournal Article
000126906 520__ $$aPediatric glioblastoma (pedGBM) is amongst the most common malignant brain tumors of childhood and carries a dismal prognosis. In contrast to adult GBM, few molecular prognostic markers for the pediatric counterpart have been established. We, therefore, investigated the prognostic significance of genomic and epigenetic alterations through molecular analysis of 202 pedGBM (1-18 years) with comprehensive clinical annotation. Routinely prepared formalin-fixed paraffin-embedded tumor samples were assessed for genome-wide DNA methylation profiles, with known candidate genes screened for alterations via direct sequencing or FISH. Unexpectedly, a subset of histologically diagnosed GBM (n = 40, 20 %) displayed methylation profiles similar to those of either low-grade gliomas or pleomorphic xanthoastrocytomas (PXA). These tumors showed a markedly better prognosis, with molecularly PXA-like tumors frequently harboring BRAF V600E mutations and 9p21 (CDKN2A) homozygous deletion. The remaining 162 tumors with pedGBM molecular signatures comprised four subgroups: H3.3 G34-mutant (15 %), H3.3/H3.1 K27-mutant (43 %), IDH1-mutant (6 %), and H3/IDH wild-type (wt) GBM (36 %). These subgroups were associated with specific cytogenetic aberrations, MGMT methylation patterns and clinical outcomes. Analysis of follow-up data identified a set of biomarkers feasible for use in risk stratification: pedGBM with any oncogene amplification and/or K27M mutation (n = 124) represents a particularly unfavorable group, with 3-year overall survival (OS) of 5 %, whereas tumors without these markers (n = 38) define a more favorable group (3-year OS ~70 %).Combined with the lower grade-like lesions, almost 40 % of pedGBM cases had distinct molecular features associated with a more favorable outcome. This refined prognostication method for pedGBM using a molecular risk algorithm may allow for improved therapeutic choices and better planning of clinical trial stratification for this otherwise devastating disease.
000126906 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000126906 588__ $$aDataset connected to CrossRef, PubMed,
000126906 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000126906 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aProto-Oncogene Proteins B-raf
000126906 7001_ $$aRyzhova, Marina$$b1
000126906 7001_ $$0P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aHovestadt, Volker$$b2$$udkfz
000126906 7001_ $$0P:(DE-HGF)0$$aBender, Sebastian$$b3
000126906 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b4$$udkfz
000126906 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b5$$udkfz
000126906 7001_ $$0P:(DE-He78)b6273c0ba3ae37a4d3d1c6b084797f2e$$aMeyer, Jochen$$b6$$udkfz
000126906 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b7$$udkfz
000126906 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b8$$udkfz
000126906 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b9
000126906 7001_ $$aZheludkova, Olga$$b10
000126906 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b11$$udkfz
000126906 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b12$$udkfz
000126906 7001_ $$0P:(DE-HGF)0$$aKulozik, Andreas E$$b13
000126906 7001_ $$0P:(DE-HGF)0$$aReifenberger, Guido$$b14
000126906 7001_ $$aJabado, Nada$$b15
000126906 7001_ $$aPerry, Arie$$b16
000126906 7001_ $$0P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aLichter, Peter$$b17$$udkfz
000126906 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b18$$udkfz
000126906 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b19$$udkfz
000126906 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b20$$eLast author$$udkfz
000126906 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-015-1405-4$$gVol. 129, no. 5, p. 669 - 678$$n5$$p669 - 678$$tActa neuropathologica$$v129$$x1432-0533$$y2015
000126906 909CO $$ooai:inrepo02.dkfz.de:126906$$pVDB
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b6273c0ba3ae37a4d3d1c6b084797f2e$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000126906 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000126906 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000126906 9141_ $$y2015
000126906 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126906 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000126906 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126906 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126906 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126906 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126906 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126906 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126906 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126906 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126906 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126906 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126906 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126906 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000126906 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000126906 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x1
000126906 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000126906 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x3
000126906 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000126906 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x5
000126906 980__ $$ajournal
000126906 980__ $$aVDB
000126906 980__ $$aI:(DE-He78)G380-20160331
000126906 980__ $$aI:(DE-He78)B060-20160331
000126906 980__ $$aI:(DE-He78)B062-20160331
000126906 980__ $$aI:(DE-He78)G340-20160331
000126906 980__ $$aI:(DE-He78)L101-20160331
000126906 980__ $$aI:(DE-He78)L401-20160331
000126906 980__ $$aUNRESTRICTED